Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

About the Study

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

What the Study Involves

Two groups of patients will be enrolled in this study:  

• One group will enroll people who have an inherited mutation in one of the following genes: ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53
• The other study group will enroll people who do not have an inherited genetic mutation, but who do have a strong family history suggestive of increased risk for prostate cancer.

Both study groups will receive the same cancer screening tests:

• physical exam (digital rectal exam)
• prostate-specific antigen (PSA) test 
• MRI of the prostate.

Study participants will be followed for up to 20 years.

Study Location

Massachusetts

• Boston, MA
  Massachusetts General Hospital
  Lead Researcher: Keyan Salari, MD, PhD
  Study coordinator: Olympia Price: 857-238-3838 or oprice@partners.org    

Men age 35-74 years old who meet the following criteria may be eligible:

• No prior diagnosis of prostate cancer
• Meets either group 1 or group 2 criteria:
  • Group 1: has an inherited mutation in one of the following genes: ATM, ATR, BRCA1, BRCA2, BRIP1, CHEK2, EPCAM, FANCA, GEN1, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, RAD51C, RAD51D, TP53.
  • Group 2: has a strong family history suggestive of high genetic risk for prostate cancer but with no inherited genetic mutation.

Men are not eligible to participate if they:

• have had a prior diagnosis or treatment of prostate cancer
• are not able to undergo a prostate MRI or receive the MRI contrast agent